Navigation Links
Delcath Systems, Inc. Completes Phase III Study Enrollment
Date:10/21/2009

NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled. This clinical study is evaluating the Delcath PHP System(TM) for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver.

With the achievement of complete enrollment, the company remains on-track for a FDA submission of its Delcath PHP System(TM) with melphalan in 2010. Trial enrollment will continue for the near-term to include additional patients that have begun the evaluation process and may be eligible to participate.

"We always expected to see the greatest enrollment activity in the second half of the study period as positive word about the Delcath PHP System spread and attracted new patients to the study," said Eamonn Hobbs, President and CEO of Delcath Systems. "We are delighted to have completed enrollment on-plan, and to continue the extremely positive momentum created over the last six months. We have achieved several key, strategic milestones, including the successful review of our Phase III safety data, orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma, and the additions of David McDonald as Chief Financial Officer and Dr. Krishna Kandarpa as Chief Medical Officer and EVP of Research and Development. We also executed on our plans to build our own manufacturing facility, which we will continue to develop as we focus for the remainder of the year on preparation for our FDA submission, commercialization and international licensing."

About the Phase
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
10. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
(Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
(Date:7/10/2014)... 2014 Best Drug Rehabilitation ... having family close by during a stay in ... or not the process is successful, has launched ... at http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success ... from several Best Drug Rehabilitation graduates who wanted ...
(Date:7/10/2014)... As the use of electronic health record becomes widespread ... implementation of the Affordable Care Act, the quantity of ... analytic purposes will also dramatically increase. Additionally, experts ... that analyze large quantities of data for the purpose ... the value of patient care a process that ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, ... hot flashes that often accompany menopause, new research suggests. ... of menopausal women, said Dr. Taraneh Shirazian, an assistant professor ... School of Medicine at Mount Sinai Hospital in New York ... hot flashes a day, and she added that hot flashes ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3
... Coaches, trainers focus on prevention, better treatment for ... -- "Getting your bell rung." "A dinger." "Knocking ... a serious problem -- a concussion. , But ... are getting a lot better at spotting a ...
... barometer - gas prices go up, major ... market trend to stay home, shop online, REDMOND, Wash., ... offering over 30,000 supplements at,savings up to 50% today announced that ... quarters of 2008 as people change shopping habits to,offset today,s high ...
... Holmes,(Amex: HH ) today announced the sale ... Claims Evaluation Division (CED), a unit providing,independent medical ... for use in evaluating claims., The sale ... purchase,price of approximately $5.6 million. In one transaction, ...
... prices, biofuels, and climate change places 1.7,billion people ... risk of hunger, warns,anti-poverty agency ActionAid., WASHINGTON, ... in Hokkaido, Japan, ActionAid launches a new report, ... Global Food Crisis and What,They Can Do to ...
... NavigatorMD, Inc., a leading,benefits intelligence, software ... of Value-Based Plan Design development, announced,the addition ... Development and,Sales., Norris brings 24 years ... including market development and management. As Director ...
... - Thyroid cancer that has spread to distant sites has ... blood vessel formation can slow disease progression in some patients, ... Texas M. D. Anderson Cancer Center reports in the July ... . , The investigational drug, motesanib diphosphate, is a VEGF ...
Cached Medicine News:Health News:Playing It Safe With High School Sports 2Health News:Playing It Safe With High School Sports 3Health News:Playing It Safe With High School Sports 4Health News:Photo: VitaminLife.com Sees Internet Sales Up 40% in Major Metro Markets as Gas Crisis Looms; Shopping Behaviors Change as People Conserve Gas 2Health News:Hooper Holmes Announces Sale of Claims Evaluation Division 2Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:Marshall Norris Joins NavigatorMD as Director of Business Development and Sales 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4
... Stryker Threaded Dilator System ... another choice for drilling ... provide compaction reaming versus ... of bone within the ...
... The USS Sports Medicine Knot Pusher is a ... arthroscopic surgery. The Knot Pusher is utilized in ... and retrieving. The two piece shaft allows the ... slot for knot pushing. The ring handle allows ...
... Arthroscopy Scissor is ideal for excising soft tissue ... in the joint. The serrated edge on the ... as hold tissue within the jaws for more ... right jaw curvatures, are the perfect tools for ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
Medicine Products: